Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial
Authors
Keywords
Locally advanced gastric cancer, Perioperative chemotherapy, Capecitabine, Oxaliplatin, Trastuzumab, HER2-positive, Phase II clinical trial
Journal
EUROPEAN JOURNAL OF CANCER
Volume 145, Issue -, Pages 158-167
Publisher
Elsevier BV
Online
2021-01-20
DOI
10.1016/j.ejca.2020.12.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010.
- (2020) Howard Safran et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.
- (2020) Ralf Dieter Hofheinz et al. JOURNAL OF CLINICAL ONCOLOGY
- Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials
- (2019) Lujia Chen et al. CANCER TREATMENT REVIEWS
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
- (2019) Salah-Eddin Al-Batran et al. LANCET
- Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO‐CLASSIC Study
- (2019) Yiyi Yu et al. ONCOLOGIST
- Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
- (2019) Fernando Rivera et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Duration of adjuvant trastuzumab: might less be more?
- (2018) O Metzger Filho et al. ANNALS OF ONCOLOGY
- The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature
- (2017) Yu-ying Lei et al. World Journal of Surgical Oncology
- HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC).
- (2017) H. H. Yoon et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
- (2014) Sung Hoon Noh et al. LANCET ONCOLOGY
- Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
- (2012) M. Terashima et al. CLINICAL CANCER RESEARCH
- HER2/neutesting for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
- (2012) Carlos Gómez-Martin et al. JOURNAL OF CLINICAL PATHOLOGY
- Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
- (2011) Marc Ychou et al. JOURNAL OF CLINICAL ONCOLOGY
- Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
- (2011) Yassir Sbitti et al. World Journal of Surgical Oncology
- Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer
- (2010) Monica Iorfida et al. BREAST
- Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report
- (2010) Jun Wang et al. Journal of Hematology & Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started